Takeshi Masuda Selected Research

Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)

3/2024	Association of immune-related adverse events with durvalumab efficacy after chemoradiotherapy in patients with unresectable Stage III non-small cell lung cancer.
11/2023	Significance of micro-EGFR T790M mutations on EGFR-tyrosine kinase inhibitor efficacy in non-small cell lung cancer.
2/2023	Association between Plasminogen Activator Inhibitor-1 and Osimertinib Tolerance in EGFR-Mutated Lung Cancer via Epithelial-Mesenchymal Transition.
1/2023	Immune checkpoint therapy and response biomarkers in non-small-cell lung cancer: Serum NY-ESO-1 and XAGE1 antibody as predictive and monitoring markers.
12/2022	Pre-Existing Interstitial Lung Abnormalities Are Independent Risk Factors for Interstitial Lung Disease during Durvalumab Treatment after Chemoradiotherapy in Patients with Locally Advanced Non-Small-Cell Lung Cancer.
11/2022	Predictive role of circulatory levels of high-mobility group box 1 for radiation pneumonitis in patients with non-small cell lung cancer treated with definitive thoracic radiotherapy.
6/2022	Characteristic computed tomography features in mesenchymal-epithelial transition exon14 skipping-positive non-small cell lung cancer.
1/2022	Phase 2 study of first-line pembrolizumab monotherapy in elderly patients with non-small-cell lung cancer expressing high PD-L1.
1/2022	First-line osimertinib treatment in a patient with lung adenocarcinoma with coexisting epidermal growth factor receptor G719S and de novo T790M mutations.
12/2021	Potential benefits of volumetric modulated arc therapy to reduce the incidence of ≥ grade 2 radiation pneumonitis in radiotherapy for locally advanced non-small cell lung cancer patients.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Takeshi Masuda Research Topics

Disease

40	Neoplasms (Cancer) 01/2024 - 11/2013
25	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 03/2024 - 06/2011
20	Lung Neoplasms (Lung Cancer) 11/2023 - 01/2018
16	Interstitial Lung Diseases (Interstitial Lung Disease) 11/2023 - 01/2018
10	Pulmonary Fibrosis (Fibrosing Alveolitis) 01/2024 - 01/2016
9	Fibrosis (Cirrhosis) 01/2024 - 01/2017
8	Lung Injury 05/2024 - 01/2017
8	Adenocarcinoma of Lung 01/2022 - 06/2011
8	Neoplasm Metastasis (Metastasis) 05/2021 - 01/2011
7	Idiopathic Pulmonary Fibrosis 05/2024 - 01/2016
7	Disease Progression 07/2022 - 12/2018
7	Carcinoma (Carcinomatosis) 05/2021 - 01/2011
6	Asthma (Bronchial Asthma) 10/2023 - 01/2017
5	Human Influenza (Influenza) 01/2024 - 08/2002
5	Renal Cell Carcinoma (Grawitz Tumor) 01/2019 - 01/2016
4	Developmental Dysplasia of the Hip 05/2024 - 06/2012
4	Leukemia 10/2023 - 04/2015
4	Adenocarcinoma 01/2023 - 10/2014
4	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2023 - 10/2017
4	Bronchiectasis 02/2021 - 01/2018
4	Inflammation (Inflammations) 01/2021 - 09/2005
3	Acute Lung Injury 05/2024 - 01/2020
3	Testicular Neoplasms (Testicular Cancer) 01/2023 - 03/2013
3	Carcinogenesis 11/2022 - 10/2020
3	Pneumonia (Pneumonitis) 10/2022 - 01/2018
3	Hemorrhage 01/2022 - 04/2005
3	Venous Thromboembolism 01/2022 - 03/2019
3	Breast Neoplasms (Breast Cancer) 01/2019 - 01/2013
3	Lewis Lung Carcinoma 09/2018 - 11/2013
3	Urinary Bladder Neoplasms (Bladder Cancer) 12/2017 - 01/2011
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 11/2022 - 12/2018
2	Radiation Pneumonitis 11/2022 - 12/2021
2	Respiratory Insufficiency (Respiratory Failure) 02/2022 - 01/2017
2	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 06/2014
2	Stroke (Strokes) 09/2021 - 12/2016
2	Emphysema 04/2021 - 01/2018
2	Thrombosis (Thrombus) 02/2021 - 03/2013
2	Hemolysis 02/2021 - 01/2020
2	Diabetes Mellitus 01/2021 - 07/2019
2	Melanoma (Melanoma, Malignant) 01/2021 - 09/2018
2	Intracranial Embolism 01/2020 - 03/2019
2	Infections 12/2019 - 09/2005

Drug/Important Bio-Agent (IBA)

18	Proteins (Proteins, Gene)FDA Link 01/2023 - 02/2008
13	Biomarkers (Surrogate Marker)IBA 05/2024 - 06/2014
10	Bleomycin (Blenoxane)FDA LinkGeneric 05/2024 - 03/2013
9	LigandsIBA 07/2022 - 01/2016
6	Plasminogen Activator Inhibitor 1IBA 02/2023 - 11/2013
6	Plasminogen Activators (Plasminogen Activator)IBA 02/2023 - 11/2013
6	Cisplatin (Platino)FDA LinkGeneric 02/2021 - 03/2013
5	CytokinesIBA 11/2023 - 01/2017
5	ErbB Receptors (EGF Receptor)IBA 02/2023 - 06/2011
5	Immune Checkpoint InhibitorsIBA 01/2023 - 09/2019
5	AntigensIBA 01/2023 - 01/2019
5	HMGB1 Protein (HMG1)IBA 01/2023 - 01/2020
5	pembrolizumabIBA 01/2022 - 03/2019
4	AntibodiesIBA 12/2019 - 12/2018
4	Zanamivir (Relenza)FDA Link 06/2009 - 08/2002
3	Messenger RNA (mRNA)IBA 01/2023 - 01/2021
3	SteroidsIBA 12/2022 - 01/2018
3	AnticoagulantsIBA 01/2022 - 03/2013
3	Small Interfering RNA (siRNA)IBA 01/2021 - 12/2015
3	NivolumabIBA 01/2020 - 01/2018
3	EnzymesIBA 12/2019 - 03/2016
3	SK-216IBA 01/2016 - 11/2013
3	Membrane Proteins (Integral Membrane Proteins)IBA 06/2014 - 02/2008
2	durvalumabIBA 03/2024 - 12/2022
2	Conditioned Culture MediaIBA 01/2024 - 01/2020
2	Hydroxyproline (4 Hydroxyproline)IBA 01/2024 - 10/2018
2	Tyrosine Kinase InhibitorsIBA 11/2023 - 01/2021
2	Nitric Oxide (Nitrogen Monoxide)FDA Link 10/2023 - 01/2021
2	Adrenal Cortex Hormones (Corticosteroids)IBA 09/2023 - 01/2022
2	osimertinibIBA 02/2023 - 01/2022
2	Prothrombin (Factor II)IBA 01/2023 - 01/2022
2	Prednisolone (Predate)FDA LinkGeneric 12/2022 - 01/2018
2	Immunoglobulin G (IgG)IBA 12/2022 - 04/2022
2	B7-H1 AntigenIBA 02/2022 - 12/2019
2	edoxabanIBA 01/2022 - 03/2019
2	Etoposide (VP 16)FDA LinkGeneric 11/2021 - 03/2013
2	Gefitinib (Iressa)FDA Link 10/2021 - 06/2011
2	Erlotinib Hydrochloride (CP 358,774)FDA Link 10/2021 - 06/2011
2	RNA Precursors (Precursor, mRNA)IBA 09/2021 - 12/2018
2	Indicators and Reagents (Reagents)IBA 02/2021 - 01/2020
2	Anti-Bacterial Agents (Antibiotics)IBA 02/2021 - 09/2005
2	Interleukin-6 (Interleukin 6)IBA 01/2021 - 01/2017
2	Gemcitabine FDA Link 01/2021 - 01/2011
2	PlatinumIBA 01/2021 - 01/2020
2	Heparin (Liquaemin)FDA LinkGeneric 03/2019 - 01/2007
2	suplatast tosilateIBA 01/2019 - 01/2017
2	ChemokinesIBA 01/2019 - 01/2017

Therapy/Procedure

20	Therapeutics 01/2023 - 09/2005
19	Drug Therapy (Chemotherapy) 07/2022 - 01/2011
7	Chemoradiotherapy 03/2024 - 10/2017
6	Hip Replacement Arthroplasty (Total Hip Replacement) 05/2024 - 09/2011
6	Radiotherapy 11/2022 - 06/2017
4	Traction 02/2021 - 01/2018
3	Cystectomy 05/2021 - 01/2011
3	Catheters 01/2020 - 12/2012
2	Oral Administration 10/2022 - 06/2017
2	Nebulizers and Vaporizers (Inhaler) 01/2022 - 09/2018
2	Nephroureterectomy 05/2021 - 06/2013